English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduBeing diagnosed with a serious illness such as cancer brings many physical, emotional and financial burdens, not only for patients, but for their caregivers as well. However, a new study from researchers at Wake Forest University School of Medicine shows that caregivers of adult cancer patients are often overlooked in cancer care.
Tag: NCORP
Roswell Park, Wilmot Cancer Institute Collaborate on First Large Study of Immunotherapy in Black Cancer Patients
A new collaboration between two Western New York cancer research leaders will help oncologists learn whether Black and white cancer patients respond differently to a game-changing immunotherapy treatment, and seeks to improve the safety and effectiveness of these newer drugs in diverse populations.
Atlantic Health System Physicians Co-Author 5 Studies, Presented at American Association for Cancer Research (AACR) Annual Meeting
Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.
Accelerating Access to Breakthrough Cancer Therapies Leads Morristown Medical Center to Expand Infusion Center
Atlantic Health System has announced the opening of Morristown Medical Center’s new state-of-the-art, patient-centered Infusion Center located in the Carol G. Simon Cancer Center. The first of three phases of expansion of New Jersey’s pre-eminent cancer center, the new unit was funded in large part by donations made by community members in support of the Foundation for Morristown Medical Center’s Growing Forward Campaign.
Cancer center exceeds NCORP clinical trial accrual goals
The University of Kansas Cancer Center’s status as a community site of the National Cancer Institute’s Community Oncology Research Program has been renewed after exceeding clinical trial accrual goals by more than 22% in its first year.